Table 1.

ALK rearrangements in cancer

Cancer typeFrequency of ALK rearrangementsALK fusion partner geneLocation of fusion partnerReferences
NSCLC3–7%TPR1q31.1(2, 40–45)
CRIM12p22.2
EML4a2p21
STRN2p22.2
TFG3q12.2
HIP17q11.23
PTPN39q31
KIF5B10p11.22
KLC114q32.3
CLTC17q23.1
ALCL∼55% (in adults)TPM31q21.3(1, 21–29)
ATIC2q35
TFG3q12.2
NPM1a5q35.1
TRAF19q33.2
CLTC17q23.1
RNF21317q25.3
TPM419p13.1
MYH922q12.3
MSNXq12
IMTUp to 50%TPM31q21.3(30–37)
RANBP22q13
ATIC2q35
SEC31A4q21.22
CARS11p15.4
PPFIBP112p11
CLTC17q23.1
TPM419p13.1
DLBCL<1%RANBP22q13(164–171)
EML42p21
SEC31A4q21.22
SQSTM15q35
NPM15q35.1
CLTC17q23.1
Colorectal cancer<1%EML42p21(172–175)
WDCP2p23.3
Breast cancerN.D.EML42p21(173)
RCC<1%TPM31q21.2(176–179)
EML42p21
STRN2p22.2
VCL10q22.2
RMCN.D.VCL10q22.2(180)
Esophageal cancerN.D.TPM419p13.1(181, 182)
Ovarian cancerN.D.FN12q35(183)
  • Abbreviations: TPR, translocated promoter region, nuclear basket protein; CRIM1, cysteine rich transmembrane BMP regulator 1; EML4, echinoderm microtubule associated protein like 4; STRN, striatin; TFG, TRK-fused gene; HIP1, huntingtin interacting protein 1; PTPN3, protein tyrosine phosphatase, nonreceptor type 3; KIF5B, kinesin family member 5B; KLC1, kinesin light chain 1; CLTC, clathrin heavy chain; ALCL, anaplastic large cell lymphoma; TPM3, tropomyosin 3; NPM1, nucleophosmin; TRAF1, TNF receptor associated factor 1; RNF213, ring finger protein 213; TPM4, tropomyosin 4; MYH9, myosin, heavy chain 9, nonmuscle; MSN, moesin; IMT, inflammatory myofibroblastic tumor; RANBP2, RAN binding protein 2; SEC31A, SEC31 homolog A; CARS, cysteinyl-tRNA synthetase; PPFIBP1, PTPRF interacting protein, binding protein 1; DLBCL, diffuse large B-cell lymphoma; SQSTM1, sequestosome 1; WDCP, WD repeat and coiled coil containing; N.D., not determined; RCC, renal cell carcinoma; VCL, vinculin; RMC, renal medullary carcinoma; FN1, fibronectin 1.

  • aEML4 and NPM1 are the most common fusion partner genes in NSCLC and ALCL, respectively.